Vesigen to Present New Preclinical Data on Engineered ARMMs Technology at 2024 ASGCT Annual Meeting

Vesigen Therapeutics, Inc. today announced that the Company will be presenting 10 posters sharing new preclinical data from its engineered ARMMs platform at the upcoming American Society of Gene & Cell Therapy (ASGCT) Annual Meeting.

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Vesigen Therapeutics, Inc., a biotechnology company developing a novel non-viral delivery platform for gene editors, RNA, and protein-based therapeutics, today announced that the Company will be presenting 10 posters sharing new preclinical data from its engineered ARMMs platform at the upcoming American Society of Gene & Cell Therapy (ASGCT) Annual Meeting. The conference will be held from May 7-11 in Baltimore, Maryland.

Vesigen’s delivery technology has been shown to be non-immunogenic and is re-dosable. ARMMs can be targeted to cell types of interest. Vesigen will be presenting new preclinical data demonstrating successful biodistribution of its ARMMs in non-human primates (NHPs). The team will also be sharing data on its new targeted ARMMs technology, demonstrating the ability to deliver to otherwise hard-to-reach cell types.

Details of the poster presentations are listed below. All posters will be presented in the poster hall of the Baltimore Convention Center at 12 PM EST.

May 8 Poster Presentations

Engineering ARMMs with Engagers to Direct Biodistribution to Specific Neurons as a Therapeutic Strategy for Friedreich Ataxia

  • Presenting Author: Wendy Zhao, Ph.D.
  • Abstract Number: 635

ARMMs as Non-Viral Vehicles for the Delivery of Genome Editors to Treat Inherited Retinal Diseases

  • Presenting Author: Qin Yu, Ph.D.
  • Abstract Number: 660

Biodistribution of ARMMs as Non-Viral Vehicles for Therapeutic Payloads by Subretinal Administration in Minipigs and Non-Human Primates

  • Presenting Author: Joseph Nabhan, Ph.D.
  • Abstract Number: 663

May 9 Poster Presentations

ARMMs as Non-Viral Vehicles for the Delivery of Therapeutic Payloads to Liver Sinusoidal Endothelial Cells

  • Presenting Author: Ryan von Kleeck, Ph.D.
  • Abstract Number: 1238

Fractionation of distinct extracellular vesicle populations by charge and density to evaluate the heterogeneity and purity of ARMMs

  • Presenting Author: Kristin Luther, Ph.D.
  • Abstract Number: 1246

ARMMs as a Versatile and Modular Non-Viral Platform for the Functional Delivery of Genome Editors

  • Presenting Author: Qiyu Wang, Ph.D.
  • Abstract Number: 1247

Engineering ARMMs with Modular T Cell-Specific Engagers for Non-Viral Delivery of Therapeutic Payloads

  • Presenting Author: Wendy Zhao, Ph.D.
  • Abstract Number: 1248

Engineering Directed Tropism in the Non-Viral ARMMs Delivery Platform

  • Presenting Author: Silvia Piccinotti, Ph.D.
  • Abstract Number: 1249

May 10 Poster Presentations

ARMMs as Non-Viral Vehicles that Enable in vivo Functional Delivery of Cas9 to Disrupt NLRP3 in Kupffer Cells and Ameliorate Acute Liver Injury

  • Presenting Author: Mike Thomas, Ph.D.
  • Abstract Number: 1736

Suspension Cell-Based Production and Scalable Purification of Engineered ARMMs as a Platform for Non-Viral Therapeutics

  • Presenting Author: Steven Greenway
  • Abstract Number: 1746

For more information about the ASGCT Annual Meeting, including registration details, please visit https://annualmeeting.asgct.org/.

About Vesigen Therapeutics
Vesigen Therapeutics is a biotechnology company developing a novel, non-viral delivery technology for gene editing, RNA, and protein-based therapeutics. Vesigen’s patented technology, called ARMMs (ARRDC1 Mediated Microvesicles), can be used to precisely deliver a wide range of payloads to a unique set of tissue and cell types. Vesigen has demonstrated highly efficient in vitro and in vivo functional delivery of a range of payloads across multiple cell types and is committed to developing transformative medicines that address current unmet medical needs. ARMMs were discovered and engineered into a drug delivery system at the Harvard T.H. Chan School of Public Health.

For additional information visit www.vesigen.com.

Contacts

Investor and Media Contact:
Adam Bero, Ph.D.
Kendall Investor Relations
abero@kendallir.com

Source: Vesigen Therapeutics, Inc.

MORE ON THIS TOPIC